Test Price
2,800 AED✅ Home Collection Available
SLC12A7 Gene Bartter Syndrome Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
This NGS-based diagnostic assay analyzes the full coding region of the SLC12A7 gene to detect pathogenic variants causative of Bartter syndrome, a hereditary renal tubulopathy characterized by salt wasting and electrolyte imbalance. The test achieves a diagnostic sensitivity of 99.9% under ISO 15189:2022 accredited processing at DNA Labs UAE.
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2022 accredited laboratory processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance on result interpretation with a DHA-licensed genetic counsellor.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The SLC12A7 gene Bartter syndrome genetic test employs Next Generation Sequencing (NGS) on the Illumina NovaSeq X platform to interrogate all coding exons, intronic boundaries, and selected regulatory regions. Sanger sequencing confirms all clinically reportable variants. The assay includes copy number variant (CNV) analysis for deletion and duplication detection. Validated for both adult and paediatric populations, this test supports clinical diagnosis, carrier screening, and family risk stratification.
| Feature | DNA Labs UAE Test | Closest Alternative |
|---|---|---|
| Methodology | NGS with Illumina NovaSeq X plus Sanger confirmation | Standard Sanger single-exon sequencing |
| Coverage | Full gene + flanking intronic regions ± CNV analysis | Partial gene, selected exons only |
| Turnaround Time | 3-4 Weeks (guaranteed) | 6-8 weeks |
Physician Insight & Safety Protocols
"A negative result on the SLC12A7 NGS panel does not exclude Bartter syndrome; clinical correlation with serum electrolyte levels, urine chemistries, and renal imaging is essential. Any management decisions should be coordinated with the treating nephrologist. This genetic test is most informative when integrated within the complete clinical and biochemical context." — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Advisory Note on Medication Safety
Do not discontinue prescribed potassium-sparing diuretics, potassium supplements, or any medication without consulting your physician before or after sample collection.
Exclusion Criteria & Urgent Clinical Guidance
- Do not collect samples during acute febrile illness or haemolytic crisis as these may compromise DNA quality.
- If the patient received an allogeneic blood transfusion within 3 weeks, inform the laboratory; donor DNA may interfere with variant detection.
- Seek emergency care immediately if the patient experiences severe dehydration, tetany, cardiac arrhythmia, or sudden visual disturbances — do not delay treatment pending genetic results.
Patient FAQ & Clinical Guidance
1. When should I consider the SLC12A7 genetic test?
This test is appropriate for individuals presenting with unexplained hypokalemic metabolic alkalosis, polyuria, nephrocalcinosis, or a family history indicative of Bartter syndrome. Genetic confirmation supports long-term management strategies, family planning decisions, and may reduce the need for repeated invasive evaluations.
2. How long does it take to receive results for the SLC12A7 genetic test?
The typical turnaround time is 3 to 4 weeks from sample receipt. This duration ensures thorough sequencing, robust bioinformatic analysis, and expert variant interpretation by our molecular geneticists. A comprehensive clinical report with post-test counselling is included.
3. Is home sample collection safe for genetic testing?
Yes. Our ISO-certified phlebotomists perform VIP Mobile Phlebotomy using a validated cold-chain protocol that preserves nucleic acid integrity, achieving diagnostic accuracy equivalent to hospital-based draws. Samples are transported in temperature-controlled containers with real-time tracking via WhatsApp.
4. Will insurance cover the SLC12A7 genetic test?
We provide direct billing verification with participating insurers. Please forward your insurance card via WhatsApp to +971 54 548 8731 for a pre-authorization check before sample collection.
UAE Regulatory & Data Privacy Adherence
This diagnostic service complies with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access-controlled, and processed exclusively within UAE jurisdiction. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE is licensed by the Dubai Health Authority (DHA) under Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | SLC12A7 Gene Bartter Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) – VIP Mobile Phlebotomy Home Collection Available |
| Methodology Used | Next Generation Sequencing (NGS) on Illumina NovaSeq X with Sanger confirmation and CNV analysis |
| ICD-10-CM Code | E26.81 (Bartter syndrome), R79.8 (Abnormal findings of blood chemistry) |
| LOINC Code | 21674-2 (Gene rearrangement and mutation analysis) |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians